The antibody sc-33040-R fails to specifically recognize phosphorylation of ErbB4 on tyrosine1056

References

• Bangalore L, Tanner AJ, Laudano AP, Stern DF. Antiserum raised against a synthetic phosphotyrosine-containing peptide selectively recognizes p185neu/erbB-2 and the epidermal growth factor receptor. Proc Natl Acad Sci USA 1992; 89(23)11637–11641
   Google Scholar
• DiGiovanna MP. Phosphorylation sensitivity of the commonly used anti-p185neu/erbB2 monoclonal antibody clone 3B5 suggests selective usage of autophosphorylation sites. Anal Biochem 1997; 247(1)167–170
   Google Scholar
• DiGiovanna MP, Stern DF. Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor. Cancer Res 1995; 55(9)1946–1955
   PubMed Web of Science ®Google Scholar
• DiGiovanna MP, Carter D, Flynn SD, Stern DF. Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours. Br J Cancer 1996; 74(5)802–806
   Google Scholar
• Elenius K, Choi CJ, Paul S, Santiestevan E, Nishi E, Klagsbrun M. Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene 1999; 18(16)2607–2615
   Google Scholar
• Epstein RJ, Druker BJ, Roberts TM, Stiles CD. Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor. Proc Natl Acad Sci USA 1992; 89(21)10435–10439
   Google Scholar
• Gallo RM, Bryant I, Fry R, Williams EE, Riese DJ, II. Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines. Biochem Biophys Res Commun 2006; 349(1)372–382
   Google Scholar
• Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ. ErbB kinases and NDF signaling in human prostate cancer cells. Oncogene 1997; 15(22)2705–2716
   Google Scholar
• Hobbs SS, Coffing SL, Le AT, Cameron EM, Williams EE, Andrew M, Blommel EN, Hammer RP, Chang H, Riese DJ, II. Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation. Oncogene 2002; 21(55)8442–8452
   Google Scholar
• Hobbs SS, Cameron EM, Hammer RP, Le AT, Gallo RM, Blommel EN, Coffing SL, Chang H, Riese DJ, II. Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase. Oncogene 2004; 23(4)883–893
   Google Scholar
• Jolivalt CG, Jiang Y, Freshwater JD, Bartoszyk GD, Calcutt NA. Dynorphin A, kappa opioid receptors and the antinociceptive efficacy of asimadoline in streptozotocin-induced diabetic rats. Diabetologia 2006; 49(11)2775–2785
   Google Scholar
• Junttila TT, Sundvall M, Maatta JA, Elenius K. Erbb4 and its isoforms: Selective regulation of growth factor responses by naturally occurring receptor variants. Trends Cardiovasc Med 2000; 10(7)304–310
   Google Scholar
• Junttila TT, Sundvall M, Lundin M, Lundin J, Tanner M, Harkonen P, Joensuu H, Isola J, Elenius K. Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res 2005; 65(4)1384–1393
   Google Scholar
• Kew TY, Bell JA, Pinder SE, Denley H, Srinivasan R, Gullick WJ, Nicholson RI, Blamey RW, Ellis IO. c-erbB-4 protein expression in human breast cancer. Br J Cancer 2000; 82(6)1163–1170
   Google Scholar
• Kumar R, Vadlamudi RK. The EGF family of growth factors. J Clin Ligand Assay 2000; 23(3)233–238
   Google Scholar
• Lyne JC, Melhem MF, Finley GG, Wen D, Liu N, Deng DH, Salup R. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. Cancer J Sci Am 1997; 3(1)21–30
   Google Scholar
• Maatta JA, Sundvall M, Junttila TT, Peri L, Laine VJ, Isola J, Egeblad M, Elenius K. Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. Mol Biol Cell 2006; 17(1)67–79
   Google Scholar
• Mann R, Mulligan RC, Baltimore D. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 1983; 33(1)153–159
   PubMed Web of Science ®Google Scholar
• Modi S, DiGiovanna MP, Lu Z, Moskowitz C, Panageas KS, Van Poznak C, Hudis CA, Norton L, Tan L, Stern DF, et al. Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer. Cancer Invest 2005; 23(6)483–487
   PubMed Web of Science ®Google Scholar
• Mulloy R, Ferrand A, Kim Y, Sordella R, Bell DW, Haber DA, Anderson KS, Settleman J. Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res 2007; 67(5)2325–2330
   PubMed Web of Science ®Google Scholar
• Onguru O, Scheithauer BW, Kovacs K, Vidal S, Jin L, Zhang S, Ruebel KH, Lloyd RV. Analysis of epidermal growth factor receptor and activated epidermal growth factor receptor expression in pituitary adenomas and carcinomas. Mod Pathol 2004; 17(7)772–780
   Google Scholar
• Ouyang X, Gulliford T, Zhang H, Huang GC, Epstein R. Human cancer cells exhibit protein kinase C-dependent c-erbB-2 transmodulation that correlates with phosphatase sensitivity and kinase activity. J Biol Chem 1996; 271(36)21786–21792
   Google Scholar
• Ouyang X, Gulliford T, Doherty A, Huang GC, Epstein RJ. Detection of ErbB2 oversignalling in a majority of breast cancers with phosphorylation-state-specific antibodies. Lancet 1999; 353(9164)1591–1592
   Google Scholar
• Ouyang X, Gulliford T, Huang GC, Harper-Wynne C, Shousha S, Epstein RJ. Multisite phosphotyping of the ErbB-2 oncoprotein in human breast cancer. Mol Diagn 2001; 6(1)17–25
   Google Scholar
• Penington DJ, Bryant I, Riese DJ, II. Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activities. Cell Growth Differ 2002; 13(6)247–256
   Google Scholar
• Pitfield SE, Bryant I, Penington DJ, Park G, Riese DJ, II. Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell lines. Oncol Res 2006; 16(4)179–193
   Google Scholar
• Riese DJ, II, van Raaij TM, Plowman GD, Andrews GC, Stern DF. The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol Cell Biol 1995a; 15(10)5770–5776
   PubMedGoogle Scholar
• Riese DJ, II, DiMaio D. An intact PDGF signaling pathway is required for efficient growth transformation of mouse C127 cells by the bovine papillomavirus E5 protein. Oncogene 1995b; 10(7)1431–1439
   Google Scholar
• Rittie L, Kansra S, Stoll SW, Li Y, Gudjonsson JE, Shao Y, Michael LE, Fisher GJ, Johnson TM, Elder JT. Differential ErbB1 signaling in squamous cell versus basal cell carcinoma of the skin. Am J Pathol 2007; 170(6)2089–2099
   Google Scholar
• Robinson D, He F, Pretlow T, Kung HJ. A tyrosine kinase profile of prostate carcinoma. Proc Natl Acad Sci USA 1996; 93(12)5958–5962
   Google Scholar
• Suo Z, Risberg B, Kalsson MG, Willman K, Tierens A, Skovlund E, Nesland JM. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 2002; 196(1)17–25
   PubMed Web of Science ®Google Scholar
• Sweeney C, Lai C, Riese DJ, II, Diamonti AJ, Cantley LC, Carraway KL, III. Ligand discrimination in signaling through an ErbB4 receptor homodimer. J Biol Chem 2000; 275(26)19803–19807
   Google Scholar
• Thelemann A, Petti F, Griffin G, Iwata K, Hunt T, Settinari T, Fenyo D, Gibson N, Haley JD. Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells. Mol Cell Proteomics 2005; 4(4)356–376
   Google Scholar
• Thor AD, Liu S, Edgerton S, Moore D, II, Kasowitz KM, Benz CC, Stern DF, DiGiovanna MP. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): A study of incidence and correlation with outcome in breast cancer. J Clin Oncol 2000; 18(18)3230–3239
   Google Scholar
• Tovey SM, Witton CJ, Bartlett JM, Stanton PD, Reeves JR, Cooke TG. Outcome and human epidermal growth factor receptor (HER) 1–4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res 2004; 6(3)R246–R251
   Google Scholar
• Van Schaeybroeck S, Karaiskou-McCaul A, Kelly D, Longley D, Galligan L, Van Cutsem E, Johnston P. Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res 2005; 11(20)7480–7489
   Google Scholar
• Williams EE, Trout LJ, Gallo RM, Pitfield SE, Bryant I, Penington DJ, Riese DJ, II. A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines. Cancer Lett 2003; 192(1)67–74
   Google Scholar
• Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003; 200(3)290–297
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2(2)127–137
   PubMed Web of Science ®Google Scholar
• Zhang K, Sun J, Liu N, Wen D, Chang D, Thomason A, Yoshinaga SK. Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J Biol Chem 1996; 271(7)3884–3890
   Google Scholar